Safety and imunogenecity of Meningococcal B Vaccine (4CMenB, Bexsero) in Healthy adults

Trial Profile

Safety and imunogenecity of Meningococcal B Vaccine (4CMenB, Bexsero) in Healthy adults

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs Meningococcal vaccine group B (Primary)
  • Indications Meningococcal group B infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 29 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top